Postmarketing adverse events of tamoxifen in male and female patients with breast cancer

Documenti analoghi

• Long‐term benefit from adjuvant tamoxifen therapy for ER + HER2− breast cancer by PR positivity
  di: Anna E. Nordenskjöld, et al.
  Pubblicazione: (2026)
• Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change
  di: Marike Gabrielson, et al.
  Pubblicazione: (2024)
• Patient‐reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials
  di: Bradley D. Menz, et al.
  Pubblicazione: (2025)
• Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients
  di: Huizi Wu, et al.
  Pubblicazione: (2024)
• Trends in the incidence of cancers of the breast and female genital tract in Harare, Zimbabwe 1990–2019
  di: Eric Chokunonga, et al.
  Pubblicazione: (2026)